http://orcid.org/0000-0002-3383-8972
References
- Neumann PJ, Thorat T, Shi J, et al. The changing face of the cost-utility literature, 1990–2012. Value Health. 2015;18:271–277.
- Neumann PJ, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 2016.
- Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic costeffectiveness models. A suggested framework and example of application. Pharmacoeconomics. 2000;17:461–477.
- Kim DD, Basu A, Duffy SQ, et al. Worked Example 1: the cost-effectiveness of treatment for individuals with alcohol use disorders: a reference case analysis. In: Neumann P, Sanders G, Russell L, et al., editors. Cost-effectiveness in health and medicine. Vol. 2. New York: Oxford University Press; 2016. p. 385–430.
- Cunningham PJ, Kohn L. Health plan switching: choice or circumstance? Health Aff (Millwood). 2000;19:158–164.
- Fishman P, Von Korff M, Lozano P, et al. Chronic care costs in managed care. Health Aff (Millwood). 1997;16:239–247.
- Cebul R, Rebitzer J, Taylor L, et al. Unhealthy insurance markets: search frictions and the cost and quality of health insurance. Am Econ Rev. 2008;101:1842–1871.
- Moreno GA, Mulligan K, Huber C, et al. Costs and spillover effects of private insurers’ coverage of hep c treatment. Am J Manag Care. 2016;22:SP236–44.
- Teja T, Michael C. Skills of the trade: the tufts cost-effectiveness analysis registry. J Benefit-Cost Anal. 2012;3:1–9.
- Institute for Clinical and Economic Review (ICER). ICER response to national pharmaceutical council comments on ICER value assessment framework. [cited 2016 Nov 18]. Available from: http://icer-review.org/wp-content/uploads/2014/01/NationalPharmaceutical-Council-comments-on-ICER-Value-Framework-Assessment-with-ICERresponses-Final1.pdf
- Goodman RA, Posner SF, Huang ES, et al. Defining and measuring chronic conditions: imperatives for research, policy, program, and practice. Prev Chronic Dis. 2013;10:E66.
- Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397–406.
- King JB, Shah RU, Bress AP, et al. Cost-effectiveness of sacubitrilvalsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4:392–402.
- Coleman CI, Limone BL, Bookhart BK, et al. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism. Thromb Res. 2014;133:743–749.
- Basu A, Ganiats TG. Discounting in cost-effectiveness analysis. In: Neumann PJ, Sanders GD, Russell LB, et al., editors. Cost-effectiveness in health and medicine. Vol. 2. New York: Oxford University Press; 2016.
- Hatoum HT, Crawford ED, Nielsen SK, et al. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2013;13:261–270.
- Magnuson EA, Farkouh ME, Fuster V, et al. Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation. 2013;127:820–831.
- Reed SD, Stewart SB, Scales CD Jr., et al. A framework to evaluate the costeffectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer. Value Health. 2014;17:545–554.